Results 191 to 200 of about 53,113 (297)

MCUB Inhibits PRKN‐Dependent Mitophagic Degradation of PD‐L1 to Promote Immune Evasion in Bladder Cancer

Advanced Science, Volume 13, Issue 5, 27 January 2026.
In bladder cancer, the overexpression of MCUB not only reduces mitochondrial calcium influx but also facilitates its binding to PRKN at Arg51, both mechanisms contribute to the impairment of PRKN‐mediated mitophagy. Consequently, the degradation of PD‐L1 is suppressed, leading to its stable expression on the tumor cell surface.
Yuan Huang, Chen Chen, Mingqiang Su, Dongqing Li, Jinge Zhang, Kuangye Long, Wenbin Nie, Shu Wei, Wei Chen, Haiyong Chen, Zhangfeng Zhong, Lina Hou, Wanlong Tan, Fei Li   +13 more
wiley   +1 more source

Disproportionality analysis of adverse events in advanced lung cancer treated with atezolizumab plus platinum-based combination chemotherapy. [PDF]

J Pharm Health Care Sci
Hazama K, Imai T, Tochikura N, Washinosu S, Ootsuka S, Hanada K.   +5 more
europepmc   +1 more source

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? [PDF]

, 2017

core   +1 more source

PD‐L1 on Tumor‐Derived Extracellular Vesicles Induces CD8+ T Cell Terminal Exhaustion and Mediates Anti‐PD‐1 Resistance in Head and Neck Squamous Cell Carcinoma

Advanced Science, Volume 13, Issue 4, 19 January 2026.
Immunotherapy fails in head and neck squamous cell carcinoma (HNSCC) due to terminally exhausted T (Texterm) cells. Tumor‐derived PD‐L1+ extracellular vesicles promote CD8‐Texterm cells differentiation by upregulating BATF. Stromal Texterm density serves as a potent biomarker for predicting immunotherapy resistance, highlighting a novel EV‐mediated ...
Ruihua Fang, Bixue Huang, Yun Li, Zhimou Cai, Yicheng Deng, Xiaoqing Cen, Wei Sun, Jinhong Zhang, Zhenglin Xu, Wenbin Guo, Yi Lyu, Shiyun Luo, Zhesheng Chen, Kexing Lyu, Weiping Wen, Wenbin Lei   +15 more
wiley   +1 more source

A comparison of pharmacometric software programs for atezolizumab population pharmacokinetic simulation. [PDF]

Eur J Clin Pharmacol
Zeng Y, Arisa O, Corvalan N, Bateman F, Schmidt K, Peer C, Figg WD.   +6 more
europepmc   +1 more source

Nanobiotechnology‐Based Approaches for Targeted Glioma Therapy

Advanced NanoBiomed Research, Volume 6, Issue 1, January 2026.
Nanoparticle systems cross the blood–brain barrier to deliver drugs precisely to glioma cells. Lipid, polymeric, and magnetic carriers enable controlled release, tumor targeting, and microenvironment modulation. These nanoplatforms enhance chemotherapy, radiotherapy, and immunotherapy, improving therapeutic efficacy while reducing systemic toxicity ...
Jinwei Li, Yibo He, Yang Zhang, Lining Arnold Ju, Yao Wang, Jianxuan Zhou, Yinying Chai, Xuhui Hui, ShiYuan Tong, Si Zhang, Yanli Tan, Yinyan Wang   +11 more
wiley   +1 more source

Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis. [PDF]

PLoS One
Xiang H, She Z, Wang L, Peng Y, Zhang L, Tan C.   +5 more
europepmc   +1 more source

Inducible T‐Cell Co‐Stimulator (ICOS) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System

Cancer Medicine, Volume 15, Issue 1, January 2026.
ICOS (inducible T‐cell co‐stimulator) and ICOS ligand (ICOSL) are part of an important, complex pathway that can lead to both immune stimulation and suppression. Both ICOS agonists and antagonists are under development as oncology therapeutics and biomarker driven approaches will be important to ascertain which patients will derive the greatest benefit
Mina Nikanjam, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Sarabjot Pabla, Mary K. Nesline, Heidi Ko, Jeffrey M. Conroy, Aung Naing, Razelle Kurzrock   +9 more
wiley   +1 more source

Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER. [PDF]

PLoS One
Gao Y, Jiang S, Cui Y, Wang Y, Yu L.
europepmc   +1 more source

Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer

, 2020
Wenhan Cheng, Daniela Di Martino, MS c, Eldon Brown, MS c, Matt Gorman, Brett Connor S, Timothy Babushok, Daniela Di Martino, Ph. D.   +9 more
openalex   +1 more source